Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
And dx is not cash generating. 2024 they expect dx to ebitda positive. Ie. Probably losing cash.
But cash geerative in 2025 (allegedly)
Way to go Mr Smith
And a dose expansion removed one month and added the next.
Do Avacta know what they are doing?
A few people mentioned at the time it was very odd to spend a Big chunk of a raise on dx when tx was in need of money.
Avacta die hard fans defended it with the usual conjecture. 'must of been a condition of the raise*. I believe that to be nonsense as avacta now looking to divest with bond ongoing.
Poor poor management from Avacta
Yes, absolutely reckless
A necessary complication? Really? If it was a condition of HCI bond, they wouldn't be trying to flog it with bond ongoing.
Exactly. And funds should not have been wasted on dx companies adding to this mess Avacta have got themselves in.
The format of the trial appears to change quarter on quarter. Obviously these things are subject to change but alongside this raise questions need to be answered
P1 has been going on for knocking on 3 years
I saw that. I just look at it from a timescale perspective. Assuming the dose expansion will take months? When will P2 start?
So what is the dose expansion phase then? I thought the 2 weekly was replacing this?
Significant Newsflow
The Company is anticipating the progression of its clinical development and research stage programmes to important value inflection points across 2024 and 2025, which includes key deliverables for the pre|CISIONTM pipeline:
· AVA6000:
o Read out of two-weekly and three-weekly dose escalation study data in late Q2 2024;
o Presentation of Phase 1 three-weekly study clinical data at AACR 2024 in April 2024; and
o Establish recommended Phase 2 dose in Q3 2024, initiating the dose expansion phase in the US in H2 2024, followed by the Phase 2 study, subject to funding and FDA approval.
Yes it does appear the 2week study us well underway. With readout end of q2.
Then a new to me.. Dose expansion study
Then p2
Brokers talk. Look how many are involved
Yep. It is just unbelievable avacta spent all that money on dx companies. To then dilute the company to the tune of 20% at 50PENCE!
And then mention divesting those companies.
It's a joke
Can someone clarify the 2 weekly, dose expansion and phase 2.
Are these. 3 separate studies?
I thought they were going straight from the 2 weekly to phase 2?
So it is no where near beginning. What was the screening patients remark all about?
Placing or no placing. The company needs to do something to negate the share price decline.
It's relentless.
Avacta very rarely mention affyxell.
Say no more.
Charles?
In his interview of a few weeks ago he was unequivocal in his 'advice' that AVCT was a 'top tip' as a prime candidate for a take over.
Now AVCT is a 'top tip' as a candidate for a 60p placing? So what has changed in the intervening weeks Charles?
'' Please don't tell me you have based your well researched and considered advice on nothing more than chat board rumours and the fact that the SP has fallen??''
Couldn't agree more.
Every other placing the share price quickly declines to the placing price and it's announced pronto.
This has been going on for a good week now. Avacta will raise one way or another but I wouldn't be super confident if I had an open short right now on the premise of a discounted placing.